Ligotin Tablet 25 mg

"Ligotin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus. * \u09b0\u09c7\u099c\u09bf\u09b8\u09cd\u099f\u09be\u09b0\u09cd\u09a1 \u099a\u09bf\u0995\u09bf\u09ce\u09b8\u0995\u09c7\u09b0 \u09aa\u09b0\u09be\u09ae\u09b0\u09cd\u09b6 \u09ae\u09cb\u09a4\u09be\u09ac\u09c7\u0995 \u0994\u09b7\u09a7 \u09b8\u09c7\u09ac\u09a8 \u0995\u09b0\u09c1\u09a8'"

"Dipeptidyl Peptidase-4 (DPP-4) inhibitor"

"Alogliptin is a DPP-4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus. Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 diabetes, concentrations of GLP-1 are reduced but the insulin response to GLP-1 is preserved."

"The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily or as directed by the physicians. * \u09b0\u09c7\u099c\u09bf\u09b8\u09cd\u099f\u09be\u09b0\u09cd\u09a1 \u099a\u09bf\u0995\u09bf\u09ce\u09b8\u0995\u09c7\u09b0 \u09aa\u09b0\u09be\u09ae\u09b0\u09cd\u09b6 \u09ae\u09cb\u09a4\u09be\u09ac\u09c7\u0995 \u0994\u09b7\u09a7 \u09b8\u09c7\u09ac\u09a8 \u0995\u09b0\u09c1\u09a8'"

"Ligotin is primarily renally excreted. Cytochrome (CYP) P450-related metabolism is negligible. No significant drug-drug interactions are observed with the CYP-substrates or inhibitors tested or with renally excreted drugs."

"History of a serious hypersensitivity reaction to Alogliptin-containing products, such as anaphylaxis, angioedema or severe cutaneous adverse reactions."

"Common side effects are nasopharyngitis, headache and upper respiratory tract infection."

"Common side effects are nasopharyngitis, headache and upper respiratory tract infection."

"Acute pancreatitis: If pancreatitis is suspected, promptly Ligotin should be discontinued. Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with Ligotin such as anaphylaxis, angioedema and severe cutaneous adverse reactions. In such cases, promptly Ligotin should be discontinued. Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality can not be excluded. If liver injury is detected, promptly interrupt Ligotin and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart Ligotin if liver injury is confirmed and no alternative etiology can be found. Hypoglycemia: When an insulin secretagogue (e.g. sulfonylurea) or insulin is used in combination with Ligotin, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycaemia. Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Ligotin or any other antidiabetic drug."

"Keep below 30\u00b0C temperature, away from light & moisture. Keep out of the reach of children."